Ligand Pharmaceuticals Incorporated (LGND): Price and Financial Metrics

Ligand Pharmaceuticals Incorporated (LGND): $61.49

0.02 (+0.03%)

POWR Rating

Component Grades








Add LGND to Watchlist
Sign Up

Industry: Biotech




#66 of 359

in industry

LGND Price/Volume Stats

Current price $61.49 52-week high $97.65
Prev. close $61.47 52-week low $57.77
Day low $61.31 Volume 132,522
Day high $62.73 Avg. volume 106,857
50-day MA $65.08 Dividend yield N/A
200-day MA $70.29 Market Cap 1.07B

LGND Stock Price Chart Interactive Chart >


  • LGND scores best on the Quality dimension, with a Quality rank ahead of 80.34% of US stocks.
  • The strongest trend for LGND is in Stability, which has been heading up over the past 177 days.
  • LGND ranks lowest in Momentum; there it ranks in the 7th percentile.

LGND Stock Summary

  • With a year-over-year growth in debt of -91.93%, LIGAND PHARMACEUTICALS INC's debt growth rate surpasses just 1.29% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, LIGAND PHARMACEUTICALS INC is reporting a growth rate of -3,708.44%; that's higher than just 0.36% of US stocks.
  • As for revenue growth, note that LGND's revenue has grown -32% over the past 12 months; that beats the revenue growth of merely 8.2% of US companies in our set.
  • Stocks that are quantitatively similar to LGND, based on their financial statements, market capitalization, and price volatility, are MAX, SII, BRDG, EXPI, and OWL.
  • LGND's SEC filings can be seen here. And to visit LIGAND PHARMACEUTICALS INC's official web site, go to

LGND Valuation Summary

  • LGND's price/sales ratio is 6.3; this is 231.58% higher than that of the median Healthcare stock.
  • LGND's price/sales ratio has moved down 2 over the prior 243 months.

Below are key valuation metrics over time for LGND.

Stock Date P/S P/B P/E EV/EBIT
LGND 2023-09-22 6.3 1.5 37.8 11.6
LGND 2023-09-21 6.3 1.5 37.9 11.7
LGND 2023-09-20 6.5 1.6 39.0 12.0
LGND 2023-09-19 6.7 1.7 40.5 12.5
LGND 2023-09-18 6.6 1.6 40.0 12.3
LGND 2023-09-15 6.6 1.6 39.6 12.2

LGND Growth Metrics

    Its year over year cash and equivalents growth rate is now at -52.93%.
  • Its 4 year net cashflow from operations growth rate is now at -177.82%.
  • The 2 year net income to common stockholders growth rate now stands at 138.66%.
LGND's revenue has moved down $654,000 over the prior 49 months.

The table below shows LGND's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 241.673 112.02 -21.292
2022-06-30 240.42 111.556 -7.973
2022-03-31 267.676 120.055 23.647
2021-12-31 277.133 78.798 57.138
2021-09-30 274.65 51.693 68.315
2021-06-30 251.663 44.413 47.891

LGND's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • LGND has a Quality Grade of C, ranking ahead of 59.87% of graded US stocks.
  • LGND's asset turnover comes in at 0.195 -- ranking 202nd of 681 Pharmaceutical Products stocks.
  • NBIX, IRWD, and MNKD are the stocks whose asset turnover ratios are most correlated with LGND.

The table below shows LGND's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.195 0.774 0.067
2021-03-31 0.162 0.837 0.054
2020-12-31 0.148 0.837 0.016
2020-09-30 0.111 0.856 0.006
2020-06-30 0.092 0.862 0.002
2020-03-31 0.073 0.889 -0.026

LGND Price Target

For more insight on analysts targets of LGND, see our LGND price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $207.00 Average Broker Recommendation 1.43 (Moderate Buy)

Ligand Pharmaceuticals Incorporated (LGND) Company Bio

Ligand Pharmaceuticals develops therapies that address the unmet medical needs of patients for a range of diseases, including hepatitis, multiple myeloma, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis, and osteoporosis. The company was founded in 1987 and is based in La Jolla, California.

LGND Latest News Stream

Event/Time News Detail
Loading, please wait...

LGND Latest Social Stream

Loading social stream, please wait...

View Full LGND Social Stream

Latest LGND News From Around the Web

Below are the latest news stories about LIGAND PHARMACEUTICALS INC that investors may wish to consider to help them evaluate LGND as an investment opportunity.

Ligand Pharmaceuticals (LGND) Dips More Than Broader Markets: What You Should Know

Ligand Pharmaceuticals (LGND) closed at $59.08 in the latest trading session, marking a -0.4% move from the prior day.

Yahoo | September 22, 2023

Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

SAN DIEGO, September 22, 2023--Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze

Yahoo | September 22, 2023

Ligand’s Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control

SAN DIEGO, September 21, 2023--Ligand’s Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI

Yahoo | September 21, 2023

Ligand (LGND) to Spin Out Pelican Subsidiary, Updates '23 View

Ligand (LGND) intends to spin out and merge its subsidiary Pelican with Primordial Genetics to form a new standalone company. Post-merger, it will own a 49.9% stake in this new company.

Yahoo | September 19, 2023

Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio

SAN DIEGO, September 18, 2023--Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio

Yahoo | September 18, 2023

Read More 'LGND' Stories Here

LGND Price Returns

1-mo -4.47%
3-mo -14.72%
6-mo -16.41%
1-year -27.82%
3-year -35.78%
5-year -77.60%
YTD -7.95%
2022 -56.75%
2021 55.31%
2020 -4.64%
2019 -23.15%
2018 -0.90%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!